Standard BioTools (LAB) Competitors $1.32 -0.03 (-2.22%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.34 +0.02 (+1.89%) As of 07/11/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAB vs. TXG, TRNS, EYPT, ALNT, CTKB, AEHR, QSI, QTRX, SENS, and MASSShould you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Standard BioTools vs. Its Competitors 10x Genomics Transcat Eyepoint Pharmaceuticals Allient Cytek Biosciences Aehr Test Systems Quantum-Si Quanterix Senseonics 908 Devices Standard BioTools (NASDAQ:LAB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends. Do analysts rate LAB or TXG? Standard BioTools presently has a consensus target price of $2.50, indicating a potential upside of 89.39%. 10x Genomics has a consensus target price of $14.13, indicating a potential upside of 10.35%. Given Standard BioTools' stronger consensus rating and higher probable upside, research analysts clearly believe Standard BioTools is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Standard BioTools 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.5010x Genomics 1 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.46 Which has more risk & volatility, LAB or TXG? Standard BioTools has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Do insiders & institutionals believe in LAB or TXG? 53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by insiders. Comparatively, 9.4% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is LAB or TXG more profitable? 10x Genomics has a net margin of -25.14% compared to Standard BioTools' net margin of -78.24%. Standard BioTools' return on equity of -22.44% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Standard BioTools-78.24% -22.44% -16.74% 10x Genomics -25.14%-23.22%-18.02% Which has preferable earnings & valuation, LAB or TXG? Standard BioTools has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStandard BioTools$174.43M2.87-$138.88M-$0.35-3.7710x Genomics$610.78M2.58-$182.63M-$1.30-9.85 Does the media favor LAB or TXG? In the previous week, 10x Genomics had 2 more articles in the media than Standard BioTools. MarketBeat recorded 3 mentions for 10x Genomics and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.88 beat 10x Genomics' score of 0.88 indicating that Standard BioTools is being referred to more favorably in the media. Company Overall Sentiment Standard BioTools Very Positive 10x Genomics Positive SummaryStandard BioTools beats 10x Genomics on 10 of the 16 factors compared between the two stocks. Get Standard BioTools News Delivered to You Automatically Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LAB vs. The Competition Export to ExcelMetricStandard BioToolsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$512.76M$2.00B$5.61B$9.11BDividend YieldN/AN/A5.24%4.01%P/E Ratio-3.7734.5627.9620.25Price / Sales2.8715.80430.8999.65Price / CashN/A56.3037.4658.16Price / Book1.048.368.045.49Net Income-$138.88M-$62.39M$3.18B$250.27M7 Day Performance-1.86%5.08%3.72%4.78%1 Month Performance22.22%7.81%3.72%7.20%1 Year Performance-32.65%6.83%29.92%17.27% Standard BioTools Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABStandard BioTools3.5842 of 5 stars$1.32-2.2%$2.50+89.4%-32.7%$512.76M$174.43M-3.77620Positive NewsTXG10x Genomics4.5104 of 5 stars$11.92-8.4%$14.96+25.5%-24.7%$1.60B$610.78M-9.171,240TRNSTranscat2.9503 of 5 stars$86.35-3.9%$114.00+32.0%-30.6%$837.47M$278.42M55.351,245News CoverageAnalyst ForecastEYPTEyepoint Pharmaceuticals1.7558 of 5 stars$9.49-2.4%$25.67+170.5%+4.5%$668.85M$43.27M-3.94120ALNTAllient2.3043 of 5 stars$37.89-2.2%$31.00-18.2%+46.6%$656.17M$516.06M64.222,525Positive NewsCTKBCytek Biosciences3.1065 of 5 stars$3.40-9.6%$5.60+64.7%-44.3%$476.24M$200.45M-37.77500AEHRAehr Test Systems3.4806 of 5 stars$14.82-5.0%$25.00+68.7%-6.6%$464.43M$66.22M19.0090News CoverageEarnings ReportAnalyst RevisionQSIQuantum-Si1.9701 of 5 stars$1.83-14.5%$3.48+89.9%+60.2%$392.69M$3.06M-2.69150QTRXQuanterix2.4058 of 5 stars$6.30-9.7%$15.60+147.6%-58.2%$348.68M$137.42M-4.85460News CoverageSENSSenseonics2.0967 of 5 stars$0.49-2.6%$1.55+216.8%+5.9%$320.11M$23.68M-3.7690News CoveragePositive NewsAnalyst ForecastAnalyst RevisionMASS908 Devices1.3159 of 5 stars$6.41-3.6%$5.33-16.8%+30.0%$238.48M$59.63M-11.8760 Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Allient Alternatives Cytek Biosciences Alternatives Aehr Test Systems Alternatives Quantum-Si Alternatives Quanterix Alternatives Senseonics Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LAB) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LAB Stock Alerts